Sarah K Perreault

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4551258/publications.pdf

Version: 2024-02-01

1307543 996954 28 233 7 citations g-index h-index papers

28 28 28 479 docs citations times ranked citing authors all docs

15

#	Article	IF	CITATIONS
1	High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leukemia and Lymphoma, 2021, 62, 1195-1202.	1.3	5
2	Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. American Journal of Health-System Pharmacy, 2021, 78, 1112-1117.	1.0	12
3	Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection. Transfusion and Apheresis Science, 2021, 60, 103069.	1.0	1
4	Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal of Infection and Chemotherapy, 2021, 27, 1700-1705.	1.7	8
5	Evaluation of the negative predictive value of methicillin-resistant <i>Staphylococcus aureus</i> nasal swab screening in patients with acute myeloid leukemia. Infection Control and Hospital Epidemiology, 2021, 42, 853-856.	1.8	4
6	Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia and Lymphoma, 2020, 61, 2955-2961.	1.3	10
7	Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 720-723.	0.4	13
8	574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases, 2020, 7, S352-S352.	0.9	0
9	1095. Investigation of Risk Factors Associated with Serious Bacterial, Viral and Invasive Fungal Infections in Hematologic Patients on Ibrutinib. Open Forum Infectious Diseases, 2020, 7, S576-S577.	0.9	O
10	1092. Increased Risk of Serious Infections in Mantle Cell Lymphoma Versus Other Hematologic Malignancies in Patients on Ibrutinib. Open Forum Infectious Diseases, 2020, 7, S575-S576.	0.9	1
11	729. Real World Efficacy of Bezlotoxumab for Prevention of <i>Clostridioides Difficile</i> Recurrence in Immunosuppressed Patients. Open Forum Infectious Diseases, 2020, 7, S415-S415.	0.9	1
12	577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose â%¥ 0.5 mg/kg/day (HD) and Low Dose &It 0.5mg/kg/day (LD) Steroid Therapy. Open Forum Infectious Diseases, 2020, 7, S353-S354.	0.9	0
13	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 246-249.	1.3	O
14	Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies. Journal of Oncology Pharmacy Practice, 2019, 25, 1305-1311.	0.9	10
15	Healthcare expenses for treatment of acute myeloid leukemia. Expert Review of Hematology, 2019, 12, 641-650.	2.2	14
16	The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease, 2019, 21, e13059.	1.7	6
17	2683. Evaluation of the Negative Predictive Value (NPV) of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Swab Screening in Acute Myeloid Leukemia Patients. Open Forum Infectious Diseases, 2019, 6, S942-S943.	0.9	O
18	2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT). Open Forum Infectious Diseases, 2019, 6, S947-S947.	0.9	0

#	Article	IF	CITATIONS
19	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1754-1758.	2.0	6
20	Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies. Supportive Care in Cancer, 2018, 26, 1979-1983.	2.2	2
21	2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand?. Open Forum Infectious Diseases, 2018, 5, S746-S746.	0.9	0
22	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 923-932.	5.2	114
23	Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient. Medical Mycology Case Reports, 2017, 17, 11-13.	1.3	11
24	Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care in Cancer, 2017, 25, 205-208.	2.2	3
25	Optimization of Voriconazole Therapy via a Validated Voriconazole Dose Modification Guideline (VDMG). Open Forum Infectious Diseases, 2016, 3, .	0.9	0
26	Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia. Journal of Oncology Pharmacy Practice, 2016, 22, 646-651.	0.9	5
27	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. Blood, 2016, 128, 1063-1063.	1.4	5
28	Voriconazole Dose Modification Guideline to Optimize Therapeutic Levels in Patients With Hematologic Malignancies. Open Forum Infectious Diseases, 2015, 2, .	0.9	2